Article Sidebar

Download
PDF

Main Article Content

Abstract


RÉSUMÉ
Introduction. Le but du travail était d’évaluer la prévalence et le niveau de connaissance des femmes VIH+ sur la vaccination contre le cancer du col et de décrire les résultats histologiques des biopsies réalisées. Matériels et méthodes. Il s’agit d’une étude descriptive, transversale, analytique avec une collecte prospective des données du 1er janvier au 30 mars 2020 au CHU Gabriel Touré de Bamako, Mali. Résultat. 216 femmes VIH positives ont réalisé le dépistage du cancer du col de l’utérus durant notre période d’étude. Parmi ces 216 cas, 16 patientes (7,4%) ont été positives au test IVA/IVL. La tranche d’âge dominante était celle de 45 - 64 ans (38,42%). Les femmes mariées monogames étaient fortement représentées. Les femmes non scolarisées représentaient 66,2% des cas. La charge virale initiale (p=0,011), l’inobservance au traitement (p=0,025), les antécédents d’infection sexuellement transmissible (P=0,002), le type de traitement d’IST (P=0,005), l’insuffisance de connaissance sur l’existence de vaccin contre HPV (P=0,022) étaient les facteurs de risque les plus retrouvés. En outre, un taux de CD4 initial inférieur ou égal à 499 c/mm3 était retrouvé chez 75% des femmes positives au dépistage du cancer du col. Le taux de prise en charge des lésions précancéreuses et cancéreuses du col s’élevait à 50%. Sur le plan histologique (8 cas sur seize biopsies réalisées), il y avait 73,5% de cancers invasifs, 12,5% de CIN et 12,5% de cervicites. Conclusion. La prévalence du cancer du col chez les femmes séropositives est de 7.4% et près de trois quarts des lésions sont des cancers invasifs. Les connaissances sur le dépistage et la vaccination sont insuffisantes.
ABSTRACT
Introduction. The aim was to assess the prevalence and level of knowledge of HIV+ women on cervical cancer vaccination, and to describe the results of the histopathology of biopsies. Materials and methods. This was a descriptive, cross-sectional, analytical study with prospective data collection from January 1 to March 30, 2020 at the Gabriel Touré University Hospital in Bamako, Mali. Result. 216 HIV positive women were screened for cervical cancer during our study period. Among the 216 seropositive women, 16 (7.4%) were tested positive after visual inspection with acetic acid (VIA) and with Lugol's iodine (VILI). Women aged 45-64 years (38.42%) were most numerous. Monogamous married women were strongly represented. Out-of-school women accounted for 66.2%. Initial viral load (p=0.011), adherence to treatment (p=0.025), history of sexually transmitted infection (P=0.002), type of STI treatment (P=0.005), poor knowledge of the existence of HPV vaccine (P=0.022) were the main risk factors. Initial CD4 count less than 499 c/mm3 was found on 75% des women who were positive for cervical cancer screening. The management rate of precancerous and cancerous lesions of the cervix was 50%. Histological analysis (8 available over 16) revealed 73.5% of invasive cancer, 12.5% of CIN and 12.5% of cervicitis. Conclusion. The prevalence of cervical cancer among seropositive women is 7.4%. About three lesions over four are invasive carcinomas. Knowledge about screening and vaccination is poor.

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite
Seydou, S., Bocoum, A., Sylla, C., Traoré, S. O., Traoré, S., Traoré, Y., TEGUETE, I. ., & Mounkoro, N. (2022). Le Cancer du Col chez les Femmes Séropositives au VIH au CHU Gabriel Toure de Bamako: Prévalence et Évaluation du Niveau des Connaissances: Cervical cancer among women living with HIV at the Gabriel Toure University Hospital of Bamako: prevalence and assessment of knowledge. HEALTH SCIENCES AND DISEASE, 23(5). https://doi.org/10.5281/hsd.v23i5.3607
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Walboomers JM, Jacobs MV, Manos M, Bosch FX, Kummer JA, Shah KV. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999; 189:12–19.
  2. CDC ( Center of Disease Control ). Anonymous 1993 revised classification system for HIV infection; 5p.
  3. Francheschi S, Jaffe H Cervical cancer screening of women living with HlV: a must in the post-ART era. Clin Infect Dis. 2007; 45:510–513.
  4. Clifford GM, Frisch M, Smith JS, Plummer M, Munoz N, France chi S, et al, human papilloma virus types in invasive cervical cancer worldwide: meta-analysis, PubMed 2003.
  5. Massad LS, Ahdieh L, Benning L, Minkoff H, Greenblatt RM, Watts H, et al. Evolution of cervical abnormalities among women with HlV-1: evidence from surveillance cytology in the women’s interagency HlV study. J Acquir Immune Defic Syndr, 2001; 27:432–442.
  6. Schuman P, Ohmit SE, Klein RS, Duerr A, Cu-Uvin S, Jamieson DJ, et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HlV)-seropositive and at-risk HlV-seronegative women. J Infect Dis, 2003; 188 :128–136.
  7. Stein L, Urban I, o’Connel et al. The spectrum of human deficiency virus associated cancers in a South Africa black population, resultant’s from a case-control study 95-2004, Int J cancer , 2004; 22:2260-2265.
  8. Leroy V, Ladner J, De Clercq A, Meheus A, Nyiraziraje M, Karita E, et al. Cervical dysplasia and HlV type infection in African pregnant women: a cross sectional study, Kigali, Rwanda. The Pregnancy and HlV Study Group (EGE). Sex Transm Infect. 1999; 75:103–106.
  9. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. Trends in cancer risk among people with AlDS in the United States 1980–2002. AIDS 20:1645–1654.
  10. Newnham A, Harris J, Evans HS, Evans BG, Moller H. The risk of cancer in HlV-infected people in southeast England: a cohort study. Br J Cancer. 2005. 92:194–200.
  11. Mbulaiteye SM, Katabira ET, Wabinga H, Parkin DM, Virgo P, Ochai R, et al. (2006). Spectrum of cancers among HlV-infected persons in Africa: The Uganda AlDS-Cancer Registry Match Study. Int J Cancer 118:985–990.
  12. SISSOKO A. Lesions précancéreuses du col de l’utérus prévalence et facteurs influençant leurs survenues chez les femmes VIH positives suivies au CESAC de Bamako, mémoire de fin d’étude en gynécologie et obstétrique 2010-2011
  13. Nienke J Veldhuijzen, Sarah L Braunstein, Joseph Vyankandondera, Chantal Ingabire, Justin Ntirushwa, Evelyne Kestelyn, Coosje Tuijn, Ferdinand W Wit, Aline Umutoni, Mireille Uwineza, Tania Crucitti, and Janneke HHM van de Wijgert,The epidemiology of human papillomavirus infection in HIV-positive and HIV-negative high-risk women in Kigali, Rwanda,Published online 2011 Dec 2. doi: 10.1186/1471-2334-11-333,PMCID: PMC3247865,PMID: 22136570.
  14. Didelot-Rousseau MN, Nagot N, Costes-Martineau V, X Valle`s, A Ouedraogo3, I Konate4, HA Weiss4, P Van de Perre, P Mayaud4 and M Segondy*, for the Yerelon Study Group Human papillomavirus genotype distribution and cervicalsquamous intraepithelial lesions among high-risk women withand without HIV-1 infection in Burkina Faso, British Journal of Cancer (2006) 95, 355 – 362 & 2006 Cancer Research UK All rights reserved 0007 – 0920/06 $30.00www.bjcancer.com.
  15. JACQUET A. Cancers du col de l’utérus et infection à VIH en Afrique de l’Ouest, Epidémiologie descriptive, déterminants et dépistage, thèse numéro 1979 pour le doctorat de l’université Bordeaux 2, Http://www.infectagentscancer.com/content/5/S1/A10, 2012
  16. Veldhuijzen Nienke J , Sarah L Braunstein, Joseph Vyankandondera, Chantal Ingabire, Justin Ntirushwa, Evelyne Kestelyn. Et coll. ,The epidemiology of human papillomavirus infection in HIV-positive and HIV-negative high-risk women in Kigali, Rwanda,Published online 2011 Dec 2. doi: 10.1186/1471-2334-11-333,PMCID: PMC3247865,PMID: 22136570
  17. Vikrant V, Sahasrabuddhe1, Ramesh A, Smita N, Anita N, Chandraprabha A, Nagwanshi R. et coll. Prevalence and Predictors of Colposcopic-Histopathologically Confirmed Cervical Intraepithelial,Neoplasia in HIV-Infected Women in India, PLoS ONE www.plosone.org , January 2010 5 ( 1 ) : e8634.
  18. Delmas MC, Larsen C, van Benthem B, Hamers FF, Bergeron C, Poveda JD, et al. Cervical squamous intraepithelial lesions in HlV-infected women: prevalence, incidence and regression. European Study Group on Natural History of HlV lnfection in Women. AIDS, 2000. 14:1775–1784.
  19. Kabeyene, A C O, Bongning D, Mendimi Nkodo, M, Sando Z, Doh A, Fewou A, Essame Oyono J. 2015. Sérotypes de Papillomavirus Humain à Haut Risque chez les Patientes Séropositives au VIH Présentant des Lésions Intra Épithéliales Cervicales. HEALTH SCIENCES AND DISEASE, 16(2). Retrieved from http://hsd-fmsb.org/index.php/hsd/article/view/524.
  20. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 97: 577–586.
  21. Six C, Heard l, Bergeron C, Orth G, Poveda JD, Zagury P, et al. Comparative prevalence, incidence and short-term prognosis of cervical squamous intraepithelial lesions amongst HlV-positive and HlV-negative women. AIDS. 1998 12:1047–1056.
  22. Harris TG, Burk RD, Palefsky JM, Massad LS, Bang JY, Anastos K, et al. lncidence of cervical squamous intraepithelial lesions associated with HlV serostatus, CD4 cell counts, and human papillomavirus test results. J Am Med Assoc. 2005 :1471–1476.
  23. Sobesky.M et al lnternational Collaboration on HlV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000. 92:1823–1830.
  24. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002. 35:1127–1134.
  25. Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HlV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet. 2002. 359:108–113.
  26. De Sanjose´ S, Palefsky J. Cervical and anal HPV infections in HlV positive women and men. Virus Res. 2002. 89:201–211.
  27. Heard l, Tassie JM, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HlV- seropositive women. AIDS. 2002 16:1799–1802.
  28. Lillo FB, Ferrari D, Veglia F, Origoni M, Grasso MA, Lodini S, et al.. Human papillomavirus infection and associated cervical disease in human immuno- deficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis. 2001. 184:547–551.
  29. RamaDjouedjon Dakenyo, Bruno Kenfack et Samuel Nambile Cumber. connaissance, attitudes et pratiques des femmes en âge de procréer du district de santé de la Mifi sur la prévention du cancer du col de l’utérus, Cameroun,the panafrican

Most read articles by the same author(s)

<< < 1 2